Considering the cost-effectiveness of statins in Family Practice in Turkey from a payer perspective

Daylan Koçkaya P., Wertheimer A., Koçkaya G.

Health, cilt.1, sa.4, ss.274-280, 2009 (Hakemli Dergi)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 1 Sayı: 4
  • Basım Tarihi: 2009
  • Doi Numarası: 10.4236/health.2009.14044
  • Dergi Adı: Health
  • Sayfa Sayıları: ss.274-280
  • Kocaeli Üniversitesi Adresli: Evet

Özet

The percentage of mortality caused by cardio-vascular events in European Countries and European Union Countries is respectively 49% and 42% of all mortality causes. Our estimates about cardiovascular mortality in Turkey depend on TEKHARF (Hearth Disease and Risk Factors in Turkish Adults) which depended on a 12 year observation. It has been reported that cardio-vascular mortality rates for Turkey in men and women were 0.082% and 0.043% respectively. In Turkey, Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin and Simvastatin are the different alternatives found in the statin market. All stat-ins are reimbursed by insurance companies. The aim of this study is to determine the cost- effectiveness of statins. In conclusion, simvas-tatin and rosuvastatin comprised the optimal two statin alternatives.